FDA
-
-
-
-
-
-
-
WAVE Life Sciences (WVE) PT Raised to $14 at Wells Fargo
-
-
-
-
-
-
-
Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Wave regains full control of WVE-006 drug from GSK partnership
-
-
-
-
-
-
-
WAVE Life Sciences (WVE) Appoints Christopher Wright as Chief Medical Officer
-
-
-
-
-
-
-
WAVE Life Sciences (WVE) announces phase 1 of clinic trial of WVE-007
-
-
-
-
-
-
-
Pre-Open Stock Movers 03/30: (MBRX) (ABCL) (SEEL) Higher; (WVE) (BFLY) (CLDX) Lower (more...)
-
-
-
-
-
-
-
Wave Life Sciences Announces Fast Track Designation from U.S. FDA for Suvodirsen
-
334,268 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


